Strategic partnerships Minerva Imaging has recently formed high-profile collaborations with Debiopharm Group and Thor Medical to advance radiopharmaceuticals and ensure lead-212 availability in Europe, creating joint demand-generation and co-development opportunities for selling radiopharmaceutical services and conjugation technology.

Leadership expansion New leadership appointments including Head of Partnering & Business Strategy and a new Chair of the board signal a strengthened governance and growth-oriented strategy, presenting an opening to engage at executive levels around strategic partnerships, advisory services, and expanded business development efforts.

Growth investor Nordic Capital’s partnership to support Minerva Imaging’s growth indicates access to strategic funding and scaling opportunities, suggesting potential for enterprise sales of comprehensive CRO and CDMO services, as well as collaboration on larger translational research programs.

Market positioning As a Denmark-based radiopharmaceutical CRO/CDMO with capabilities in targeted radionuclide therapies and in vivo molecular imaging, Minerva Imaging presents a compelling cross-vertical value proposition for oncology, cardiovascular disease research, and translational drug development requiring integrated manufacturing and research services.

Upcoming visibility Active participation in major scientific events and recent AACR activity, plus ongoing engagement with industry partners, suggests growing brand awareness and demand signals in radiation therapy research, offering opportunities for outreach to lead programs seeking specialized radiopharmaceutical expertise.